Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040)
South Korea · Delayed Price · Currency is KRW 5,640.00
-10.00 (-0.18%)
At close: Apr 21, 2026
Kyung Dong Pharmaceutical Revenue
In the year 2025, Kyung Dong Pharmaceutical had annual revenue of 196.27B KRW with 1.20% growth. Kyung Dong Pharmaceutical had revenue of 52.16B in the quarter ending December 31, 2025, with 5.32% growth.
Revenue
196.27B
Revenue Growth
+1.20%
P/S Ratio
0.77
Revenue / Employee
560.78M
Employees
350
Market Cap
151.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 196.27B | 2.34B | 1.20% |
| Dec 31, 2024 | 193.94B | 31.26B | 19.22% |
| Dec 31, 2023 | 162.67B | -20.04B | -10.97% |
| Dec 31, 2022 | 182.72B | 5.11B | 2.88% |
| Dec 31, 2021 | 177.61B | 3.78B | 2.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DongKoo Bio & Pharma | 242.69B |
| Daehan Nupharm | 202.40B |
| HYUNDAI BIOLAND | 130.51B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 106.44B |
| KOREA PHARMA | 87.60B |
| OPTUS Pharmaceutical | 87.16B |
| High Tech Pharm | 70.18B |
| Vivozon Pharmaceutical | 59.34B |